bcl-6和Ki-67在弥漫大B细胞淋巴瘤中的表达及其意义

Expressions and significance of bcl-6 and Ki-67 in diffuse large B-cell lymphoma

目的研究bcl-6和Ki-67在弥漫大B细胞淋巴瘤（DLBCL）中的表达及其临床意义。方法应用免疫组织化学方法检测90例DLBCL标本中bcl-6和鼬-67的表达情况。以20例淋巴结反应性增生（RH）标本作为对照。结果bcl-6在DLBCL组织中阳性表达率为54．44％（49／90），在RH组织中为15．00％（3／20），两者差异有统计学意义（χ2=10．214，P=0．001）；其表达与临床分期、乳酸脱氢酶水平、B症状及Hans分型相关（χ2值分别为5．257、5．257、4．704、16．024，均P〈0．05）。Ki-67在DLBCL组织中的高表达率为80．00％（72／90），而在RH组织中为20．00％（4／20），两者差异有统计学意义（χ2=27585，P=0．000），其表达与临床分期、国际预后指数（IPI）及近期疗效相关（χ2值分别为5．889、6．451、6．024，均P〈0．05）。结论bcl-6和Ki-67的异常表达与DLBCL的临床分期、IPI及Hans分型等相关，可为其临床治疗及预后判断等提供参考依据。

Objective To study the expressions and significance of bcl-6 and Ki-67 in diffuse large B-cell lymphoma（DLBCL）. Methods Immunohistochemistry technique was used to detect the expressions of bcl-6 and Ki-67 in the tissues of 90 DLBCL patients. 20 cases of reactive hyperplasia of lymph node （RH） were used as control. Results Positive expression rate of bcl-6 are 54.44 %（49/90）, 15.00 %（3/20） in DLBCL or RH tissues respectively （χ2=10.214,P=0.001）. There were correlations between bcl-6 expression and Ann Arbor clinical stage, LDH, B symptoms, or Hans classification （χ2=5.257,5.257,4.704,16.024 respectively, all P〈0.05）. The high expression rate of Ki-67 were 80.00 %（72/90）, 20.00 %（4/20）in DLBCL or RH tissues respectively （X2=27.585,P=0.O00）. There were correlations between Ki-67 expression and Ann Arbor clinical stage, IPI or recent effect （χ2=5.889, 6.451, 6.024 respectively, all P〈0.05）. Conclusion There are significant correlations between the aberrant expression of bcl-6 or Ki-67 and Ann Arbor clinical stage, IPI or Hans classification. The expressions of bcl-6 and Ki-67 may provide important information for the clinical therapy and prognosis of DLBCL.